A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Genentech, Inc.
Study ID
NCT07609719
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • OCR SC — DRUG
    Participants will receive OCR SC as per the schedule specified in the arm and the United States Prescribing Information (USPI).

Study Details

The purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered subcutaneously (SC) in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS) after switching from another anti-cluster of differentiation 20 (aCD20) therapy approved for RMS (ofatumumab SC, ublituximab-xiiy intravenous \[IV\], ocrelizumab IV) or PPMS (ocrelizumab IV).

Key Dates

Start date
Jul 15, 2026
Status verified
May 2026
Primary completion
Feb 28, 2029
Completion
Feb 28, 2029

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: OCR SC
    Participants will receive OCR SC, 920 milligrams (mg) at Day 1 and at Week 24.

Primary Outcome Measure

Percentage of Participants With no Change or Reduction From Baseline in Number of T1 Gadolinium-enhanced (Gd+) Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) at Week 24 [ Time Frame: Baseline, Week 24 ]

Central Contacts

  • Reference Study ID Number: ML46740 https://forpatients.roche.com/
    888-662-6728 (U.S.)
    [email protected]

Locations (10)

FacilityCityStateZIPSite coordinators
Alabama Neurology AssociatesBirminghamAlabama35209-
Clinical EndpointsScottsdaleArizona85258-
Advanced Neurology of ColoradoFort CollinsColorado80528-
Neurology Associates - MaitlandOrlandoFlorida32751-
Multiple Sclerosis Center of Atlanta/Atlanta Neuroscience InstituteAtlantaGeorgia30327-
Minneapolis Clinic of NeurologyMinneapolisMinnesota55422-
Ohio State University, Multiple Sclerosis and Neuroimmunology CenterColumbusOhio43210-
Neurology Clinic, P.C.CordovaTennessee38018-
DHR Health MS CenterMcAllenTexas78501-
MultiCare Institute for Research & InnovationTacomaWashington98405-

Find similar trials in Birmingham, AL

By condition
Multiple sclerosis
By specialty
NeurologyBrain disordersAutoimmune disease
By research site
Alabama Neurology Associates· Birmingham, ALClinical Endpoints· Scottsdale, AZAdvanced Neurology of Colorado· Fort Collins, CONeurology Associates - Maitland· Orlando, FLMultiple Sclerosis Center of Atlanta/Atlanta Neuroscience Institute· Atlanta, GAMinneapolis Clinic of Neurology· Minneapolis, MN

Related Studies